Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

55.12 -0.77 (-1.38%)
Streaming Delayed Price Updated: 11:05 AM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Viking Global Dumps UnitedHealth, Loads Up On Disney, McDonald's, JPMorgan, AMD In Q2 Shake-Up ↗
Via Benzinga
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Preview: Travere Therapeutics ↗
 
Via Benzinga
News headline image
Travere Therapeutics Inc (NASDAQ:TVTX) Surpasses Q2 2025 Expectations with Strong Revenue Growth and Narrower Loss ↗
Travere Therapeutics (TVTX) reported strong Q2 2025 results, beating revenue and earnings estimates, driven by FILSPARI sales and milestone payments. Shares rose 2.3% post-earnings. 
Via Chartmill
News headline image
Travere Therapeutics Reports Second Quarter 2025 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Participate at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Report Second Quarter 2025 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Demystifying Travere Therapeutics: Insights From 8 Analyst Reviews ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
7 Analysts Assess Travere Therapeutics: What You Need To Know ↗
 
Via Benzinga
News headline image
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>